Financial Shenanigans

The Forensic Verdict

Iridium's reported numbers look like a faithful representation of economic reality, but two accounting judgment areas do real work in propping up the FY2024–FY2025 earnings recovery and deserve underwriting before sizing a position. The single biggest swing factor is the Q4 2023 extension of satellite useful lives from 12.5 to 17.5 years, which dropped depreciation and amortization from $320M in FY2023 to $203M in FY2024 — a $117M tailwind that almost exactly equals the $118M increase in operating income over the same period. The second is a $19.8M one-time gain on the step-up of a pre-existing equity stake in Satelles when the company acquired full control in April 2024, which represented roughly 18% of FY2024 net income. There is no evidence of revenue manipulation, working-capital lifelines, or non-GAAP gamesmanship; auditor relationship is clean (KPMG since 2022, all audit fees, no non-audit fees, no restatement); and FY2025 cash flow growth came from operations, not balance-sheet pressure. The grade is Watch (32/100). The single data point that would most change the grade is the magnitude of the next-generation satellite capex program — capex has run at half of D&A for two years and a sudden ramp would expose the depreciation extension as having merely deferred expense recognition into a future capex cycle.

Shenanigans Scorecard — All 13 Categories

Breeding Ground

The breeding-ground risk profile is benign with one dimension worth flagging: the management runway is unusually long. CEO Matt Desch has been in role since 2006 (19 years) and Chairman Robert Niehaus has been on the board since 2008. Together they span the entire post-bankruptcy public-company history of Iridium. Long tenure is not a red flag in itself; here it sits alongside an independent audit committee, a recent CFO transition (Vincent O'Neill in January 2025), majority-independent board, fully variable CEO pay (88% bonus per third-party disclosure), and a clean clawback policy adopted in 2023. The four newest independent directors (Frazier 2021, Sears 2022, Yeaney 2023, Shivanandan and Alterman 2025) bring fresh oversight.

The auditor signal is constructive on every dimension that matters. KPMG was appointed in 2022 (replacing Ernst & Young, who had served from emergence to 2021), so partner rotation has not yet been required. Total fees were $1,141,000 in FY2025 versus $1,117,511 in FY2024, all of it audit and audit-related — no tax services, no advisory fees, no perception of an independence problem. Insider activity over the last twelve months consists of 36 Form 4s; the only open-market sale was a 5,833-share disposal by the Iridium Satellite LLC CAO totaling $185K. Every other officer and director "sale" is either a non-discretionary tax-withholding transaction on RSU vesting (code F) or a grant (code A). That is not an exit pattern.

Earnings Quality

FY2024–FY2025 GAAP earnings expansion is largely driven by an accounting estimate change disclosed in Q4 2023, not by underlying operating leverage. Management extended the depreciable life of the satellite constellation from 12.5 to 17.5 years, citing engineering data on satellite health. The estimate change is GAAP-permissible, was disclosed in the FY2023 10-K, and matches what Iridium has communicated about Block 1 satellite performance — but the magnitude is unusual.

D&A dropped $117M between FY2023 and FY2024, and operating income improved $118M over the same period. After the estimate change, capex has run at $70-100M per year against $203-210M of D&A — a capex-to-D&A ratio of 34-48%. That is sustainable only if Iridium genuinely needs less reinvestment than the prior straight-line schedule implied. Management's investor-day commentary supports this: the constellation was re-launched as recently as 2017–2019 and the fleet still carries on-orbit spares. But every dollar of unrecognized depreciation today is a dollar of capex that must reappear in the next decade when Iridium NEXT successor satellites are ordered. The MD&A confirms that the next program ("Iridium NTN Direct" and PNT enhancements) is already drawing capex — FY2025 capex jumped 43% to $100M, and FY2026 guidance is "consistent with 2025."

The second source of headline-flattering items in FY2024 sits below operating income: a $19.8M gain on the step-up revaluation of Iridium's pre-existing equity stake in Satelles when it was acquired for $111M on April 1, 2024. This gain ran through "Gain (loss) on equity method investments," not revenue, but it inflated FY2024 net income by ~18%. In FY2025 the same line was a $2.8M loss as Aireon-related equity-method results turned negative. Cleaning out both items, the FY2024 to FY2025 net income compare is approximately $93M to $117M (+26%), versus the as-reported $113M to $114M (+1%) — i.e., underlying earnings growth is meaningfully better than the headline suggests, but FY2024 was the period that benefited from the one-time gain.

Revenue quality is clean. Days sales outstanding has been remarkably stable at 39-43 days for five years and improved in FY2025 (receivables fell 5% on revenue growth of 5%). The largest single revenue source — the EMSS contract with the U.S. government — is a flat $110.5M per year through expiration in September 2026. Engineering and support service revenue grew 26% in FY2025 driven by the Space Development Agency contract, but this is straightforward time-and-materials recognition. There is no contract-asset bulge, no unbilled receivable acceleration, and no change in revenue recognition policy.

One earnings-quality footnote that does not rise to a flag: inventory roughly doubled from $40M at end of FY2022 to $91M at end of FY2023, mostly subscriber-equipment hardware. It then drew down to $74M by FY2025. Management attributed the build to expected commercial demand and supply-chain hedging. Inventory days went from 73 days to 148 days and are now 109 days — elevated, but the pattern is consistent with a build-and-burn cycle, and the FY2025 MD&A explicitly discloses an "increase in inventory reserves associated with revaluation and obsolescence." That is the right disclosure to expect.

Cash Flow Quality

Operating cash flow is the cleanest part of the forensic picture. CFO has compounded steadily — $250M (FY2020) → $303M (FY2021) → $345M (FY2022) → $315M (FY2023) → $376M (FY2024) → $400M (FY2025) — and every year of that growth has been backed by net income plus depreciation, not by working-capital releases. The FY2025 MD&A explicitly states that working capital was a $10M drag on operating cash flow.

The persistent gap between CFO and net income (3-year average ratio of 4.5x) is the natural consequence of $200M+ of annual non-cash depreciation and would shrink mechanically if the satellite useful-life extension were ever reversed. CFO/revenue is 46%, which is high for a telecom but reasonable for a fixed-cost satellite operator with low marginal customer-acquisition cost.

There is no evidence of any of the four cash-flow shenanigan archetypes:

Where the cash-flow story does deserve a yellow flag is on acquisition-adjusted free cash flow. FY2024 FCF of $306M would have been $195M after subtracting the $111M Satelles acquisition. FY2025 had no acquisition outflow, so FCF of $300M is fully comparable. In FY2024 alone, acquisitions plus stock buybacks ($408M) plus dividends ($65M) totaled $584M — well above $376M of CFO — funded by a $325M Term Loan upsize. Management used the depreciation-life tailwind in part to justify a leveraged capital-return cycle.

Metric Hygiene

Iridium's preferred non-GAAP metric is "Operational EBITDA" (OEBITDA), defined as earnings before interest, taxes, depreciation and amortization plus adjustments for share-based compensation, transaction costs, change in fair value of derivatives, and similar items. The company reports OEBITDA every quarter with a full reconciliation to GAAP net income — that is the right disclosure standard. Two issues are worth tracking.

The first issue is that OEBITDA adds back share-based compensation, which has averaged $52-63M annually and equals roughly 13% of FY2025 CFO. The reconciliation is transparent — you can see the add-back — but readers comparing OEBITDA across satellite peers should ensure they treat SBC consistently. The second is that Iridium's stated 3.6x net leverage uses OEBITDA in the denominator. On GAAP EBITDA (operating income $236M + D&A $210M = $446M for FY2025), net debt of $1.66B implies 3.7x — essentially identical, so this is not abusive labelling. But the metric does sit in the operative range of the credit agreement: management triggered an excess-cash-flow sweep of $28.6M in May 2025 because the consolidated first-lien net leverage ratio at YE2024 exceeded 3.5x. It dropped below 3.5x at YE2025, so the FY2026 sweep was avoided.

What to Underwrite Next

The forensic verdict for Iridium is closer to a footnote than a position-sizing limiter, but five items warrant explicit monitoring at next disclosure: